Cargando…

The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes

PURPOSE: BMI1, which is a major component of the polycomb group complex 1, is an essential epigenetic repressor of multiple regulatory genes and has been identified as a cancer stem cell (CSC) marker in several cancers. However, its role in breast cancer (BC) remains to be defined. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Althobiti, Maryam, Muftah, Abir A., Aleskandarany, Mohammed A., Joseph, Chitra, Toss, Michael S., Green, Andrew, Rakha, Emad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320923/
https://www.ncbi.nlm.nih.gov/pubmed/32524353
http://dx.doi.org/10.1007/s10549-020-05719-x
_version_ 1783551345988468736
author Althobiti, Maryam
Muftah, Abir A.
Aleskandarany, Mohammed A.
Joseph, Chitra
Toss, Michael S.
Green, Andrew
Rakha, Emad
author_facet Althobiti, Maryam
Muftah, Abir A.
Aleskandarany, Mohammed A.
Joseph, Chitra
Toss, Michael S.
Green, Andrew
Rakha, Emad
author_sort Althobiti, Maryam
collection PubMed
description PURPOSE: BMI1, which is a major component of the polycomb group complex 1, is an essential epigenetic repressor of multiple regulatory genes and has been identified as a cancer stem cell (CSC) marker in several cancers. However, its role in breast cancer (BC) remains to be defined. In this study, we have evaluated the prognostic significance of BMI1 among the different molecular subtypes and assessed its association with other breast CSC markers (BCSC). MATERIAL AND METHOD: BMI1 copy number and mRNA was assessed in large and well-characterised cohorts of early-stage BC patients [METABRIC (n = 1980) and the Bc-GenExMiner (n = 9616) databases]. BMI1 protein expression was assessed using tissue microarray and immunohistochemistry in a cohort of 870 invasive BC patients with long-term outcome data and the expression of a panel of BCSC markers was monitored. RESULT: BMI1 expression, prognostic significance and its association with BCSC markers were differed between molecular classes. In the luminal oestrogen receptor-positive (ER+) BC, BMI1 showed significantly higher expression compared to ER− tumours. BMI1 showed positive correlation with favourable prognostic features and it was negatively associated with the expression of key BCSC markers (ALDH1A1, CD24, CD44, CD133, SOX10 and SOX9). High expression of BMI1 was associated with longer breast cancer-specific survival (BCSS) independent of other prognostic variables. In the basal triple negative BC subtype, BMI1 expression showed positive association with CD133 and SOX10 and it was significantly associated with shorter BCSS. CONCLUSION: High BMI1 expression is associated with clinicopathological variables and outcome in BC. However, this association is dependent on the molecular subtypes. Further functional assessment to detect its underlying mechanistic roles in BC subtypes is warranted. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-020-05719-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7320923
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-73209232020-07-01 The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes Althobiti, Maryam Muftah, Abir A. Aleskandarany, Mohammed A. Joseph, Chitra Toss, Michael S. Green, Andrew Rakha, Emad Breast Cancer Res Treat Preclinical Study PURPOSE: BMI1, which is a major component of the polycomb group complex 1, is an essential epigenetic repressor of multiple regulatory genes and has been identified as a cancer stem cell (CSC) marker in several cancers. However, its role in breast cancer (BC) remains to be defined. In this study, we have evaluated the prognostic significance of BMI1 among the different molecular subtypes and assessed its association with other breast CSC markers (BCSC). MATERIAL AND METHOD: BMI1 copy number and mRNA was assessed in large and well-characterised cohorts of early-stage BC patients [METABRIC (n = 1980) and the Bc-GenExMiner (n = 9616) databases]. BMI1 protein expression was assessed using tissue microarray and immunohistochemistry in a cohort of 870 invasive BC patients with long-term outcome data and the expression of a panel of BCSC markers was monitored. RESULT: BMI1 expression, prognostic significance and its association with BCSC markers were differed between molecular classes. In the luminal oestrogen receptor-positive (ER+) BC, BMI1 showed significantly higher expression compared to ER− tumours. BMI1 showed positive correlation with favourable prognostic features and it was negatively associated with the expression of key BCSC markers (ALDH1A1, CD24, CD44, CD133, SOX10 and SOX9). High expression of BMI1 was associated with longer breast cancer-specific survival (BCSS) independent of other prognostic variables. In the basal triple negative BC subtype, BMI1 expression showed positive association with CD133 and SOX10 and it was significantly associated with shorter BCSS. CONCLUSION: High BMI1 expression is associated with clinicopathological variables and outcome in BC. However, this association is dependent on the molecular subtypes. Further functional assessment to detect its underlying mechanistic roles in BC subtypes is warranted. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-020-05719-x) contains supplementary material, which is available to authorized users. Springer US 2020-06-10 2020 /pmc/articles/PMC7320923/ /pubmed/32524353 http://dx.doi.org/10.1007/s10549-020-05719-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Preclinical Study
Althobiti, Maryam
Muftah, Abir A.
Aleskandarany, Mohammed A.
Joseph, Chitra
Toss, Michael S.
Green, Andrew
Rakha, Emad
The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
title The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
title_full The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
title_fullStr The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
title_full_unstemmed The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
title_short The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
title_sort prognostic significance of bmi1 expression in invasive breast cancer is dependent on its molecular subtypes
topic Preclinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320923/
https://www.ncbi.nlm.nih.gov/pubmed/32524353
http://dx.doi.org/10.1007/s10549-020-05719-x
work_keys_str_mv AT althobitimaryam theprognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes
AT muftahabira theprognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes
AT aleskandaranymohammeda theprognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes
AT josephchitra theprognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes
AT tossmichaels theprognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes
AT greenandrew theprognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes
AT rakhaemad theprognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes
AT althobitimaryam prognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes
AT muftahabira prognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes
AT aleskandaranymohammeda prognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes
AT josephchitra prognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes
AT tossmichaels prognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes
AT greenandrew prognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes
AT rakhaemad prognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes